CNPR FDA Regulations 4 — Questions and Answers
Question 1: Which of the following best describes 'Accelerated Approval' under FDA regulations?
- Approval based on direct evidence of clinical benefit in Phase II trials
- Approval based on a surrogate endpoint reasonably likely to predict clinical benefit, with confirmatory trials required (Correct answer)
- Approval without any clinical trial data using computational models
- Approval granted exclusively for rare pediatric diseases
Correct answer: Approval based on a surrogate endpoint reasonably likely to predict clinical benefit, with confirmatory trials required
Accelerated Approval allows the FDA to approve drugs based on surrogate endpoints (like tumor shrinkage) while requiring manufacturers to conduct confirmatory trials proving actual clinical benefit.
Question 2: Under the Controlled Substances Act (CSA), which DEA schedule includes drugs with accepted medical use but the highest potential for abuse, such as oxycodone and fentanyl?
- Schedule I
- Schedule II (Correct answer)
- Schedule III
- Schedule IV
Correct answer: Schedule II
Schedule II drugs have a high potential for abuse, are currently accepted for medical use, and may lead to severe psychological or physical dependence.
Question 3: What is the primary role of the FDA's MedWatch program?
- Monitoring pharmaceutical advertising compliance
- Voluntary and mandatory reporting of serious adverse events and product problems (Correct answer)
- Tracking prescription drug pricing trends
- Certifying pharmaceutical sales representatives
Correct answer: Voluntary and mandatory reporting of serious adverse events and product problems
MedWatch is the FDA's Safety Information and Adverse Event Reporting Program, allowing healthcare professionals and consumers to report problems with drugs and medical products.
Question 4: A pharmaceutical company's promotional piece claims their drug is 'safe' without qualification. How does FDA view this claim?
- Acceptable if the drug has received FDA approval
- Misleading, because no drug is completely safe and such claims must be qualified (Correct answer)
- Acceptable if accompanied by a full prescribing information page
- Required to reinforce patient confidence in approved medications
Correct answer: Misleading, because no drug is completely safe and such claims must be qualified
FDA considers unqualified safety claims misleading because all drugs carry some risk, and such claims create a false impression about the drug's risk profile.
Question 5: The Drug Supply Chain Security Act (DSCSA) requires pharmaceutical manufacturers to implement which key capability by 2023?
- Electronic real-time prescription monitoring
- Serialized tracking and tracing of prescription drug packages through the supply chain (Correct answer)
- Mandatory electronic prescribing for all controlled substances
- Biometric verification for all pharmaceutical sales representatives
Correct answer: Serialized tracking and tracing of prescription drug packages through the supply chain
DSCSA mandates a serialized, electronic system to track and trace prescription drug packages through the entire supply chain to prevent counterfeiting and diversion.
Question 6: Under FDA regulations, what is required when a pharmaceutical company becomes aware of new safety information that changes a drug's benefit-risk profile?
- Wait for the next scheduled NDA renewal to update labeling
- Submit a labeling supplement to update the prescribing information promptly (Correct answer)
- Issue a voluntary press release only
- Notify only the prescribers who have used the drug
Correct answer: Submit a labeling supplement to update the prescribing information promptly
Manufacturers must submit a Prior Approval Supplement or Changes Being Effected supplement to update labeling when significant new safety information emerges.
Question 7: Which of the following activities by a pharmaceutical sales representative would be considered a violation of FDA promotional regulations?
- Leaving FDA-approved package inserts with physicians
- Claiming a drug is effective for a use not listed in its approved labeling (Correct answer)
- Discussing published clinical trial results that support the approved indication
- Responding to a physician's question about dosing with information from the prescribing information
Correct answer: Claiming a drug is effective for a use not listed in its approved labeling
Promoting a drug for unapproved (off-label) indications violates FDA regulations, as approved promotional claims must align with FDA-approved labeling.
CNPR FDA Regulations 4
Which of the following best describes 'Accelerated Approval' under FDA regulations?